Skip to main content

Table 1 Demographic information for enrolled clinically suspected early stage AD subjects

From: Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease

Amyloid PET Positive Negative All
Numbers (% female) 22 (50.0%) 30 (36.7%) 52 (42.3%)
Age (years) 72.1 ± 7.6 71.9 ± 9.7 72.0 ± 8.8
Education (years) 12.0 ± 4.3 11.0 ± 3.6 11.4 ± 3.9
Clinical stage
 aMCI 8 25 33
 Mild dementia 14 5 19
APOE ε4 carrier 12 2 14
CDR 0.5 0.5 0.5
MMSE 24.0 ± 2.7 27.0 ± 2.2 25.8 ± 2.8
Logical memory delayed recall 5.41 ± 3.92 8.40 ± 5.12* 7.13 ± 4.84
  1. Abbreviations: AD Alzheimer’s disease, CDR Clinical Dementia Rating Scale, MMSE Mini-Mental State Examination, PET positron emission tomography
  2. *P value < 0.05
  3. P value < 0.001